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single natural stop codon mutation in L-endoglin (sited 
within 50–55 nucleotides of the final exon-exon boundary) 
is unlikely to generate functional protein since it replaces the 
entire transmembrane domain, as would 8 further natural 
stop codon mutations, if the minor S-endoglin isoform were 
implicated in HHT pathogenesis. Finally, next-generation 
RNA sequencing data of 7 different RNA libraries from pri-
mary human endothelial cells demonstrate that multiple in-
tronic regions of  ENG  are transcribed. The potential conse-
quences of heterozygous deletions or duplications of such 
regions are discussed. These data support the haploinsuffi-
ciency model for HHT pathogenesis, explain why final exon 
mutations have not been detected to date in HHT, empha-
sise the potential need for functional examination of non-
PTC-generating mutations, and lead to proposals for an al-
ternate stratification system of mutational types for HHT 
genotype-phenotype correlations. 
 Copyright © 2013 S. Karger AG, Basel 
 Hereditary haemorrhagic telangiectasia (HHT, also 
known as Osler Weber Rendu syndrome) is one of the 
most common disorders to be inherited as an autosomal 
dominant trait [Guttmacher et al., 1995; Shovlin, 2010]. 
Careful epidemiological studies reveal that it affects ap-
 Key Words 
 Alternative splicing · Nonsense-mediated decay · Pervasive 
transcription · Premature termination codons 
 Abstract 
 Hereditary haemorrhagic telangiectasia (HHT) is a disease 
characterised by abnormal vascular structures, and most 
commonly caused by mutations in  ENG, ACVRL1  or  SMAD4 
encoding endothelial cell-expressed proteins involved in 
TGF-β superfamily signalling. The majority of mutations re-
ported on the HHT mutation database are predicted to lead 
to stop codons, either due to frameshifts or direct nonsense 
substitutions. The proportion is higher for  ENG (67%) and 
 SMAD4  (65%) than for  ACVRL1  (42%), p < 0.0001. Here, by fo-
cussing on  ENG, we report why conventional views of these 
mutations may need to be revised. Of the 111 stop codon-
generating  ENG mutations, on ExPASy translation, all except 
one were premature termination codons (PTCs), sited at 
least 50–55 bp upstream of the final exon-exon boundary of 
the main endoglin isoform, L-endoglin. This strongly sug-
gests that the mutated RNA species will undergo nonsense-
mediated decay. We provide new in vitro expression data to 
support dominant negative activity of stable truncated en-
doglin proteins but suggest these will not generate HHT: the 
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proximately 1 in 5,000 individuals [Bideau et al., 1992; 
Kjeldsen et al., 1999; Dakeishi et al., 2002]. Causative gene 
mutations (most commonly in  ENG, ACVRL1 and 
 SMAD4 ) lead to the development of abnormal vascular 
structures which cause the major complications of the 
disease. Nosebleeds and chronic gastrointestinal bleeding 
result from telangiectasia in the nasal and gastrointestinal 
tracts; complex organ-specific pathology results from the 
presence of larger arteriovenous malformations in the 
pulmonary, hepatic, cerebral, pancreatic, spinal and oth-
er circulations [Shovlin, 2010].
 Currently, 5 types of HHT are recognised. The major-
ity of HHT patients will have HHT1 due to mutations in 
 ENG encoding endoglin [McAllister et al., 1994] or HHT2 
due to mutations in  ACVRL1  encoding activin receptor-
like kinase (ALK1) [Johnson et al., 1996]. As summarised 
elsewhere [Govani and Shovlin, 2009; Shovlin, 2010], 
more than 500 different mutations have been found in 
 ENG  (HHT1) and  ACVRL1  (HHT2) HHT families (www.
hhtmutation.org at time of submission, now at www.
arup.utah.edu/database/hht/). One to two percent of cas-
es have mutations in  SMAD4,  mutations that also cause 
the gastrointestinal epithelial precancerous state of juve-
nile polyposis [Gallione et al., 2004, 2010]. There are at 
least 2 further unidentified genes that can cause pure 
HHT,  HHT3 [Cole et al., 2005; Govani and Shovlin, 2010] 
and HHT4  [Bayrak-Toydemir et al., 2006a], to date, each 
identified in single families. While all cause a wide spec-
trum of potential phenotypic consequences, genotype-
phenotype correlations indicate significant differences 
between HHT1, HHT2, and juvenile polyposis/HHT 
(JPHT), particularly with respect to the prevalence of pul-
monary, cerebral and hepatic arteriovenous malforma-
tions [Kjeldsen et al., 2005; Bayrak-Toydemir et al., 2006b; 
Bossler et al., 2006; Letteboer et al., 2006; Lesca et al., 2007; 
Sabbà et al., 2007], and the JPHT-specific pathologies as-
sociated with juvenile polyposis [Gallione et al., 2004, 
2010].
 The genes mutated in HHT encode endothelial cell-
expressed proteins that transmit or regulate signals by the 
transforming growth factor (TGF)-β superfamily of li-
gands. These ligands (including TGF-βs, activins, bone 
morphogenetic proteins (BMPs), growth/differentiation 
factors (GDFs) and inhibins) [Heldin et al., 1997; Massa-
gue and Chen, 2000; Miyazono et al., 2001] signal through 
heteromeric complexes comprised of type I and type II 
cell surface receptor serine-threonine kinases [Wrana et 
al., 1994]. Endoglin is a transmembrane glycoprotein, 
highly expressed on endothelial cells. L-endoglin, the pre-
dominant form in endothelial cells, has a cytoplasmic tail 
of 47 amino acids including 19 Ser/Thr residues; S-endo-
glin shares the identical extracellular and transmembrane 
domains, but due to retention of the penultimate intron, 
has a truncated cytoplasmic tail of 14 amino acids [Bellón 
et al., 1993]. Endoglin interacts with multiple superfam-
ily receptor complexes [Abdalla and Letarte, 2006; Lebrin 
and Mummery, 2008].  ACVRL1  encodes ALK1, a rela-
tively endothelial cell-specific TGF-β type I receptor that 
can associate with 2 type II receptors, TβRII and BMPR2 
[Bertolino et al., 2005]. TβRII also associates with TβRI 
(also known as ALK5), with activation of the alternate 
ALK1/ALK5 pathways generating different, and mutu-
ally antagonistic downstream cellular responses [Gou-
mans et al., 2003; Lebrin et al., 2004; Blanco et al., 2005, 
2008]. The precise ligand(s) responsible for the HHT 
phenotype is/are not yet determined [Park et al., 2008; 
Upton et al., 2009], with models proposed for both 
TGF-β1 [Goumans et al., 2003; Lebrin et al., 2004, 2010; 
Blanco et al., 2005; Pece-Barbara et al., 2005] and the 
ALK1-specific ligand, BMP9 [David et al., 2007; Schar-
pfenecker et al., 2007; Bailly, 2008].
 For endoglin, a body of evidence indicates that the 
HHT gene mutations lead to reduced endoglin expres-
sion at  ∼ 50% of normal in activated monocytes, human 
umbilical vein endothelial cells [Pece et al., 1997; Pece-
Barbara et al., 1999; Bourdeau et al., 2000; Cymerman et 
al., 2000; Paquet et al., 2001] and blood outgrowth endo-
thelial cells [Fernandez et al., 2006]. There are individual 
mutations which cannot generate a mutated protein, 
most obviously the single base change mutations disrupt-
ing the  ENG start codon [Gallione et al., 1998] and non-
sense mutations or large deletion mutations in which 
only the wild type allele could be detected at an RNA lev-
el [Shovlin et al., 1997; Gallione et al., 1998]. A high pro-
portion of HHT-causing mutations generate stop codons 
either directly by nonsense mutations, or as a result of 
out-of-frame deletions and/or insertions. An early model 
proposed was that translation of truncated proteins from 
the mutated  ENG  allele would lead to interference with 
the normal function of the protein from the wild type al-
lele in a dominant negative manner [McAllister et al., 
1995]. Naturally occurring truncated endoglin protein 
moeities do exist, for example the rare S-endoglin isoform 
which is increased in senescent endothelial cells [Blanco 
et al., 2008], and a soluble form of endoglin protein [Ven-
katesha et al., 2006]. Each of these exhibits functions that 
can be interpreted as dominant negative activity when co-
expressed with L-endoglin [Venkatesha et al., 2006; Blan-
co et al., 2008]. The HHT mutational relevance of these 
data, and similar evidence for dominant negative activity 
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of endoglin derived from recombinant intron-less endo-
glin cDNA expression constructs in vitro [Lux et al., 
2000] is, however, not clear: when endogenous mutated 
endoglin protein species are examined by metabolic la-
belling of cells from HHT1 patients, it is rare for any mu-
tant species to be detected [Pece et al., 1997; Pece-Barba-
ra et al., 1999; Cymerman et al., 2000]. For only 2 of 16 
 ENG  mutations studied could the mutated endoglin pro-
tein be detected in human umbilical vein endothelial cells 
or activated monocytes. These were splice site mutation 
c360+1G>A, resulting in an in-frame exon 3 skip [Pece et 
al., 1997; Cymerman et al., 2000], and missense substitu-
tion T157C [Cys53Arg] [Pece-Barbara et al., 1999; Cy-
merman et al., 2000]. In each case, the mutant proteins 
were retained intracellularly at low levels [Pece et al., 
1997; Pece-Barbara et al., 1999; Cymerman et al., 2000].
 To summarise, currently it is believed that in most if 
not all cases, HHT results from endoglin or ALK1 haplo-
insufficiency, that is the mutational inactivation of one 
allele, such that the remaining wild type allele is unable to 
contribute sufficient protein for normal function [Shov-
lin, 2010]. Recent attention has focused on the cellular 
mechanisms underlying the generation of HHT telangi-
ectasia and arteriovenous malformations, invoking de-
fective responses to angiogenic stimuli in particular set-
tings [Park et al., 2009; Lebrin et al., 2010; Mahmoud et 
al., 2010]. In contrast, the molecular mechanisms in-
volved in  ENG  HHT mutations have not been subjected 
to detailed recent scrutiny. In this article, we present new 
data that prompt a re-evaluation of the concepts regard-
ing the most common HHT mutations.
 Methods 
 HHT Gene Analyses 
 HHT  causing mutations were downloaded from the HHT mu-
tation database (www.hhtmutation.org at time of submission, now 
at www.arup.utah.edu/database/hht/) and classified into each of 
the conventional mutational types. Figures were generated using 
Microsoft Excel. The number of times each mutation in  ENG  and 
 ACVRL1 had been reported in different families was recorded as a 
categorical variable. Graphs and one phase exponential decay 
models were constructed using GraphPad Prism 5.00 (GraphPad 
Software, San Diego, Calif., USA).
 Premature Termination Codon Analyses 
 The alternate frame reads for the L-endoglin and S-endoglin 
were determined by ExPASy translation of FASTA RefSeq se-
quences NM_001114753.1 and NM_000118.2, and stop codons as-
signed to the endoglin exon map.
 ENG mutations predicted to generate frameshift mutations 
were analysed by ExPASy (www.expasy.org) to translate and de-
termine the exact site of the first stop codon generated. These were 
correlated to the known positions of stop codons in alternate read-
ing frames. For stop codons generated directly by single nucleotide 
nonsense substitutions, exon position was determined by eye. The 
relative position of each stop codon to the final 3 ′ exon-exon 
boundary of L-endoglin and S-endoglin was determined using 
RefSeq sequences NM_001114753.1 and NM_000118.2, to classify 
the stop codons as either premature termination codons (PTCs; 
more than 50–55 nucleotides upstream of the final exon-exon 
boundary) or natural stop codons within 50–55 nucleotides of the 
final exon-exon boundary.
 Endoglin Expression Data 
 The coding sequences for naturally occurring L-endoglin and 
S-endoglin were excised from the previously described pCEXV-
EndoL and pCEXV-EndoS vectors [Bellón et al., 1993] and ligated 
into pcDNA3.1Zeo+ (Invitrogen). A construct corresponding to 
an exon 13 stop codon was created by PCR-based site-directed 
mutagenesis of the pCEXV-EndoL template to introduce a stop 
codon in place of the second cytoplasmic amino acid of endoglin 
(I588X). To provide an additional control for transient transfec-
tion (and to explore a role for the 2 cytoplasmic serine residues 
conserved between L- and S-endoglin), a full length L-endoglin 
construct in which Ser590 and Thr592 were mutated to alanines 
was also created by PCR-based site-directed mutagenesis of the 
pCEXV-EndoL template, employing a PCR overlap extension 
method (details available on request). Both constructs were ampli-
fied by PCR, ligated into pGEM ® -T easy (Promega) for sequenc-
ing validation, prior to ligation into pcDNA3.1Zeo+. Insert orien-
tation and sequence was confirmed at all stages and the final prod-
ucts resequenced prior to use. All transfections were performed 
using Polyfect reagent (Qiagen) according to the manufacturer’s 
instructions. Luciferase activity was measured using a Luclite kit 
and TopCount luminometer, both from Packard Biosciences. Lu-
ciferase activity was measured 48 h after initial transfection.
 L6E9 rat myoblast cells that had been mock-transfected, or 
stably expressing L-endoglin [Letamandía et al., 1998], were a 
kind gift of Dr. Carmelo Bernabeu, and maintained in DMEM/10% 
FBS/G418/L-glutamine, and penicillin/streptomycin. L6E9 cells 
stably expressing L-endoglin were transfected with empty vector 
(mock transfections), S-endoglin, or one of the endoglin mutants, 
and analysed within 48 h. For Western blots, total cell proteins 
were extracted from transiently and stably transfected cells using 
a Triton X-100/Tris/NaCl/EDTA solution, electrophoresed un-
der non-reducing conditions on a 7.5% acrylamide gel (Bio-Rad), 
transferred to a nitrocellulose membrane, and blocked overnight 
in 5% skim milk powder in PBS-Tween. Endoglin protein was 
 detected using the monoclonal mouse anti-human endoglin 
 antibody SN6h (Dako) and an anti-mouse IgG-horse radish 
 peroxidase conjugate (Sigma)/chemiluminescence (Renaissance, 
Dupont-NEN) strategy. For luciferase assays, mock and L-endo-
glin-expressing L6E9 rat myoblast cells were transfected with 
empty vector or one of the endoglin variants, and the p800PAI-1-
Luc plasmid, a generous gift of Dr. D. Rifkin. Luciferase activity 
was measured 48 h after initial transfection, and raw data of 5 
replicates entered into GraphPad Prism. For statistical analyses, 
group data were compared using the Kruskal Wallis test using a 
post estimation multiple comparison test (Dunn’s) to derive pair-
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wise p value statistics for the 3 transient transfectants compared 
to the parental L-transfected line. For Northern blots, mock and 
L-endoglin-expressing L6E9 rat myoblast cells were transiently 
transfected with empty vector or one of the endoglin variants, and 
incubated in the absence or presence of 3 μg/ml TGF-β1 (Sigma) 
for 24 h, before extraction of total RNA using TriReagent (Sigma). 
Approximately equal amounts of RNA were size-separated on a 
1.5% agarose/formaldehyde gel, and transferred to a GeneScreen 
Plus membrane and fixed. A  32 P-dATP-labelled fragment of exon 
2 of the rat  c-myc gene amplified using primers S 5 ′ -CGACGAG-
GAAGAGAATTTGTATCA and AS 5 ′ -GAATGGACGAGGTA-
CAGGATT was hybridised to the membrane for subsequent au-
toradiographic exposure. Following appropriate decay, the mem-
brane was then hybridised to a  32 P-dATP-labelled fragment of rat 
β-actin (amplified using S 5 ′ -AAAACTGGAACGGTGAAGGC, 
AS 5 ′ -GCCTCAACACCTCAAACCAC), to allow for subsequent 
normalisation of loading differences. Image densities for each 
band were quantified using Adobe Photoshop to calculate the 
mean, median and standard deviation across the selected number 
of pixels.
 Pervasive Transcription across Endoglin Locus – Evidence in 
Endothelial Cells 
 Total RNA was extracted from 7 different confluent cultures of 
proliferating primary human microvascular endothelial cells, as 
described in Shovlin et al. [2010]. Using RNA sequencing methods 
described in detail elsewhere (Mollet et al., manuscript in prepara-
tion, methodological details supplied), Illumina small RNA sam-
ple prep kit was used to prepare directional whole transcriptome 
libraries for RNAseq. For each of the 7 libraries, 8 p M was used for 
cluster generation and sequencing on separate lanes on Genome 
Analyser II, following the standard protocol for single 76-base 
reads. Image processing and base-calling was performed with RTA 
version 1.6.47.1. To generate the endoglin transcript data, the de-
multiplexed RNAseq reads were aligned to the human endoglin 
gene region from assembly hg18 (chr9: 129616500–129660000) 
using Seqmap [Jiang and Wong, 2008]. Base calls with phred 
scores below 20 were converted to Ns and alignments were per-
formed allowing 2 mismatches per read and a minimum read 
length of 25 nucleotides. An average read depth of 2 was obtained 
outside repeat masked regions. Absolute read depth plots were cre-
ated with R (www.r-project.org), highlighting regions for repeat 
masking in black on the negative axis.
 Results 
 Breakdown of HHT Mutational Types 
 As illustrated in  figure 1 A, many more HHT muta-
tions are reported for ENG and  ACVRL1 than for  SMAD4. 
 In all 3 genes, HHT disease-causing mutations include 
insertions and deletions and single nucleotide substitu-
tions. No individual mutation is particularly common: 
For  ENG and  ACVRL1,  the number of times each indi-
vidual mutation was reported corresponded to first-order 
exponential decay ( ENG  r 2 0.997; ACVRL1  r 2 0.997), sug-
gesting that the pattern of mutations was random ( fig. 1 C).
 As shown in  figure 1 A, B, single nucleotide substitu-
tions in all 3 genes include nonsense mutations (which 
generate 1 of the 3 triplet stop codons), missense substitu-
tions (particularly common in  ACVRL1 ) and splice site 
mutations. Mutations of the start site have been reported 
only for  ENG  to date.
 For subexon and multiexon insertion and deletion 
mutations, in-frame mutations, where the reading frame 
is restored after deletion/insertion of one or more groups 
of 3 nucleotides, are less common than frameshift muta-
tions. Frameshift mutations generate stop codons be-
cause the 2 alternate reading frames contain frequent stop 
codons, with one usually reached within 1 or 2 exons of 
the frameshift. For example, for the open reading frame 
of  ENG,  the 2 alternate 5 ′ to 3 ′ reading frames contain 18 
and 16 stop codons, respectively.
 Stop codon generation is also predicted for approxi-
mately two-thirds of multiexon deletions/insertions, and 
splice site mutations, because of frameshifts in the RNA 
transcript. Using these calculations, 57% (95% confi-
dence interval 53%, 61%) of HHT mutations reported on 
the HHT database will lead to stop codons, either as a re-
sult of frameshifts or direct nonsense substitutions. The 
proportion is higher for  ENG (67% [95% confidence in-
terval 62%, 73%]) and  SMAD4  (65% [55%, 75%]) than for 
 ACVRL1 (42% [35%, 47%]) (p < 0.0001).
 Premature Termination Codons and 
Nonsense-Mediated Decay 
 Nonsense-mediated decay (NMD) has previously 
been implicated in the failure to identify RNA species for 
individual  ENG  nonsense mutations [Shovlin et al., 1997]. 
Examining the mechanisms of NMD allows a more glob-
al approach to HHT mutations, since in mammals, the 
PTC required to trigger NMD [Doma and Parker, 2007] 
is required to be a stop codon sited more than 50–55 nu-
cleotides upstream of the final exon-exon junction [Ma-
quat, 2005]. The distribution of stop codons generated by 
HHT mutations was therefore examined.
 First, each mutation was assigned to 1 of 3 groups ac-
cording to whether these could or could not generate a 
stop codon ( fig. 2 ). Focussing on the 111 mutations which 
definitely generate stop codons directly or by frameshift 
mutations ( fig. 2 , group A), the sites of predicted stop co-
dons were analysed. As shown in  table  1 and  figure 3 , 
these stop codons were sited in exons 2 to 12. Only one 
was within 55 nucleotides of the final exon-exon bound-
ary for L-endoglin. The remainder fulfil the requirements 
to act as PTCs, suggesting that the mutants will fail to 
generate an RNA product from which translation of trun-
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cated proteins could occur. For the minor alternatively 
spliced isoform, S-endoglin, 8 mutations were predicted 
to result in natural stop codons in exon 12.
 To define whether these distributions were likely to 
have occurred by chance, the pattern of stop codons with-
in the 3 alternate reading frames for  ENG  was examined 
further. Throughout all 3 reading frames, the stop codon 
prevalence between the ATG start and true stop codons 
was 34/658 codons. In any of the 3 reading frames, L-en-
doglin has only a single stop codon throughout the last 55 
nucleotides of exon 13 and the 124 coding nucleotides of 
exon 14. The probability that no stop codons would be 
present in any frame for these 59 codons is ([658–
34]/658) 59 , that is p < 0.05.
 Natural Stop Codon Considerations 
 It would be predicted that were HHT nonsense muta-
tions to generate a natural stop codon within the last 55 
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 Fig. 1. Mutational types in HHT.  A ,  B Comparison for all known 
HHT genes with pie chart representation of the different muta-
tional types. The number in the centre of each pie refers to the to-
tal number of mutations reported at the time of analysis. The co-
lour-coding explained in the schematic key in  B is used to illustrate 
the relative prevalence of the different mutational types and to em-
phasise different genomic DNA mutational types with similar 
transcript consequences: single nucleotide substitutions are sub-
classified conventionally as missense, nonsense, splice site and 
start codon mutations; deletions and insertions are sub-classified 
to emphasise the proportion generating nonsense codons and in-
clude complex rearrangements. Nonsense codons are generated by 
all direct nonsense single nucleotide substitutions (green); all sub-
exon frameshift (FS) deletions (pale blue) and insertions (lilac) but 
no subexon inframe (IF) insertions or deletions; approximately 
two-thirds of multiexon and full exon deletions, insertions and re-
arrangements (aqua, orange and pale green), and approximately 
two-thirds of splice site mutations (red).The formal assignment of 
splice site mutations and multiexon deletions to frameshift or non-
frameshift groupings depends upon evidence of the mutant endo-
glin RNA species generated – activation of cryptic splice sites may 
generate an inframe, detectable RNA species [Shovlin et al., 1997] 
instead of a more obvious exon skip that would lead to a frameshift. 
 C The distribution of the number of times each individual  ENG or 
 ACVRL1  mutation was reported (illustrated as columns), with the 
respective best fit one phase exponential decay model illustrated. 
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nucleotides of exon 13 and the 124 coding nucleotides of 
exon 14, the mutated L-endoglin protein moiety (with the 
transmembrane domain encoded by exon 12) might be 
stably expressed. We therefore re-examined unpublished 
data that we had performed as part of a previous project, 
generating expression constructs encoding a highly rele-
vant moiety, an endoglin species with the shortest possi-
ble cytoplasmic tail equivalent to a stop codon in the sec-
ond cytoplasmic codon (I588X,  fig. 4 A). Under non-re-
ducing conditions, this, and a control construct encoding 
a species in which the 2 cytoplasmic residues conserved 
between L- and S-endoglin (Ser590 and Thr592) were 
mutated to alanines, were expressed as dimers, at similar 
expression levels to transiently transfected S-endoglin 
( fig. 4 B).
 Such expressed moieties would have the potential to 
have functional consequences, potentially demonstrating 
the dominant negative activities, as observed for S-endo-
glin [Blanco et al., 2008] and soluble endoglin [Venkate-
sha et al., 2006]. This was examined by testing the effects 
of these constructs in established functional assays. As 
previously demonstrated [Letamandía et al., 1998; Blanco 
et al., 2008], activity of the plasminogen activator inhibi-
tor (PAI-1) promoter was downregulated in L6E9 myo-
blasts stably expressing L-endoglin, and this response was 
abrogated in cells transiently overexpressing S-endoglin 
( fig. 4 C). Transiently transfecting the truncated endoglin 
species into L6E9 myoblasts stably expressing L-endoglin 
also appeared to partially restore the activity of the PAI-1 
promoter, whereas the full-length cytoplasmic tail phos-
phorylation mutant had no effect ( fig.  4 C). S-endoglin 
and the truncation mutant also demonstrated similar re-
sponses in a c-myc assay where TGF-β1 downregulated 
c-myc [Letamandía et al., 1998; Blanco et al., 2008]: Once 
corrected for differential loading, the fall in c-myc in re-
sponse to TGF-β1, a response enhanced in cells stably 
transfected with L-endoglin, was not observed when 
L6E9 cells stably expressing L-endoglin were transiently 
transfected with S-endoglin or the truncated mutant 
( fig. 4 D). Furthermore, both S-endoglin and the trunca-
tion mutant also altered the predominant c-myc tran-
script expressed [Bentley and Groudine, 1986, 1988] 
(http://genome.ucsc.edu). These data demonstrate that 
an endoglin species containing a post-transmembrane 
domain stop codon, is not only likely to be translated, but 
also may have similar activities to S-endoglin, the produc-
tion of which is highly regulated [Blanco et al., 2008]. 
Such moieties would not be predicted to act as endoglin 
nulls, as for the PTC-containing mutants.
 Additional Complexity for Multiexon Deletions 
 Multiexon deletions and insertions are frequently re-
ported in HHT ( fig. 1 ). To assess if the loss of intronic 
sequences spanned by the deletions were likely to be im-
portant, we examined data from our directional RNAseq 
programme of RNA libraries constructed from 7 differ-
A
C
B
14b
9BExon 1 2 3 4 5 6 7 8 9A 10 11 12 13 1413A
10 11 12 13 14a 14c
163 4 8 8 16 14 14 10 10 22 6
6 4 2 3 2 2 4 4 3 3 1
1 2 3 4 5 6 7 8 9 
 Fig. 2. Schematic of  ENG HHT mutations mapped to exons in L-
endoglin, classified into 3 groups.  A Site of stop-generating muta-
tions: nonsense (number in boxes) and frameshift from indels 
(number below curved arrow, indicating stop codons generated 
downstream by frameshift to an alternate reading frame).  B Non-
stop codon-generating mutations: missense (grey arrows), in-
frame insertions ( ▼ ), and in-frame deletions ( ▲ ).  C Mutations 
where 2 out of 3 are predicted to generate stop codons: splice site 
mutations (clustered arrows), and large deletions, insertions and 
rearrangements (black horizontal bars). White numbers in exons: 
exon numbering as in HHT database (1–9A, 9B–14, denoting 
S-en doglin retained intron as exon 13A). Black numerals below 
exons: RefSeq numbering (1–14c, denoting S-endoglin retained 
intron as exon 14b). 
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Table 1.  Detailed breakdown of  ENG stop codon-generating mutations, by exon in which stop codon occurs (site of origin is indicated 
in fig. 2)
Stop codon 
exon
Mutations
1 –
2 c.63delC (Thr22fs); c.90T>A (Cys30X); c.97C>T (Gln33X); c.121G>T (Glu41X); c.142C>T (Gln48X); c.159C>A (Cys53X); c.166C>T 
(Gln56X); c.107delG (Gly36fs); c.115delA (Arg39fsX42)
3 c.229C>T (Gln77X); c.247C>T (Gln83X); c.277C>T (Arg93X); c.360C>A (Tyr120X); c.277delC (Arg93fs)
4 c.214_215delCC (Pro72AsnfsX76); c.298_299delAG (Ser100CysfsX48); c.305delA (Asn102ThrfsX61); c.326_327delTC (Leu109fs); 
c.332_338delCCCTGGG (Ala111fs); c.344delC (Pro115fs); c.447G>A (Trp149X); c.511C>T (Arg171X); c.392delC (Pro131fs); c.461delG 
(Gly154fsX162); c.472_472delCT (Ser158fsX160)
5 c.496delC (Gln166fsX221); c.526C>T (Glu176X); c.587G>A (Trp196X); c.588G>A (Trp196X); c.574delC (ArgfsX221); c.617delG 
(Gly206Alafs); c.640_644delGGCC (Gly214fs); c.644delA (His215fs); c.647delA (Lys216fs); c.604_607delinsCCC (Ala202ProfsX20); 
c.586_604delTGGCGGCC (p.Trp196fs...)
6 c.715G>T (Glu239X); c.782G>A (Trp261X); c.704delC (Thr235fs)
7 c.537_538delGT (Ser180fs); c.591_619del29 (Pro198fsX125); c.831C>G (Tyr277X); c.889C>T (Gln297X)
8 c.653insC (His219fs); c.657_658delCA (Ile220fsX332); c.682_686delTCGGC (Ser228fs); c.733delG (Gly245fs); c.736delG (Asp246fs); 
c.740delT (Asp248fs); c.771delC (Pro257fsX358); c.772delT (Tyr258fs); c.775delG (Val259fs); c.785_789delTCATC (Leu262fsX331); 
c.834_837delCTTC (Phe279fs); c.893delG (Gly298fsX358); c.967_968delGT (Val323fs); c.820_826delACTGGAGinsTTGAAGGTCTTTCC
AGAGAAAAAC (Thr274fsX338 ); c.1010C>G (Ser337X); c.1050T>A (Cys350X); c.1078C>T (Gln360X); c.1123G>T (Glu375X); c.995delG 
(Gly332fsX358); c.1085delA (Lys362fs)
9A c.1089_1090delTG (Ala363fs394X); c.1097_1119del23(Asp366GlufsX22); c.1111_1133del23(Val371fs); c.1120_1123delAAAG (Lys374fs); 
c.1124_1125delAG (Leu375fs); c.1243C>T (Gln415X); c.1186delG (Ala396fsX420); c.1195delA (Arg399fs); c.1199delG (Gly400fsX420); 
c.1205delA (Lys402SerfsX19); c.1206delG (Leu402fs); c.1255delA (Ser419fs)
9B c.1292C>A (Ser431X); c.1306C>T (Gln436X)
10 c.1365C>A (Tyr455X); c.1414C>T (Gln472X)
11 c.1268delA (Asn423fsX490); c.1310delG c.1334delT (Met445Argfs); c.1342_1343delCT (Ser449fsX490); c.1346_1347delCT (Ser449fsX499); 
c.1347_1350delTTTC (Phe450fs); c.1410delG (Gly470fsX490); c.1415_1417delAGA insGT (Gln472fsX490 ); c.1513G>T (Glu505X) 
c.1611C>A (Tyr537X) c.1678C>T (Gln560X); c.1684C>T (Gln562X) c.1432_1433delAG (Arg478fs); c.1472_1475delACAG (Asp491-
AlafsX26); c.1478delG (Ser492fsX516); c.1479delC (His494fsX517); c.1526delG (Gly509fs); c.1550_1551delTG (Val517fsX525); 
c.1553_1554delGC (Ser518fs); c.1554_1555delCC (Leu519fs); c.1605_1627del23 (535fs); c.1609delT (Tyr537fsX551); c.1630delA(Thr544fs)
12 c.1655delC (Ala552fs); c.1657delC (Leu553fs); c.1672_1684delGGGTCT (Gln558fsX568); c.1689_1699delAGTCCA (Glu563fsX574); 
c.1687delG (Glu563LysfsX10); c.1698delG (Arg566fs); c.1712delG (Arg571fs); c.1715T>A (Leu572X) 
13 –
14 c.1733_1737delACCTG (Asp578fs)
Note that the table excludes 2 reported frameshift mutations where the genomic DNA mutation translated inframe (c.993_1134del; c.887_918del32, 
919_920insCAAGCTCCCAG); 2 reported intronic deletions in introns 4 and 7 (c.524_689del; c.992-25_1120del152); the 5′UTR-exon 1 deletion deleting 
the start codon; and c.1-?_67+?del; c.896del186; and c1350C>T which translate as no amino acid change.
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 Fig. 3. Summary of group A  ENG  mutations generating stop co-
dons. Results are presented for L-endoglin transcript (the major 
transcript) ( A ) and for the S-endoglin transcript ( B ) for which, due 
to retention of the final intron, the final exon-exon junction is be-
tween exons 12 and 13 and not exons 13 and 14 (see fig. 4), with 
implications for stop codon mutations in exon 12. 
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ent primary human microvascular endothelial cell cul-
tures. As illustrated in  figure 5 A, there was a quasinormal 
distribution of transcripts spanning  ENG  exons, with the 
expected sharp delineation of exon-intron borders usu-
ally observed. Of importance to the large multiexon dele-
tions of  ENG  in HHT patients, however, numerous tran-
scribed fragments from the intronic regions were con-
sistently detected in these endothelial-specific libraries 
( fig. 5 B). In some cases, these were recognised to align to 
repetitive regions in the genome, and origin from the 
 ENG locus could not be assumed (inset,  fig.  5 C), but 
many represented unique alignments to the  ENG  locus 
( fig. 5 B). Importantly, as a directional sequencing strat-
egy had been employed, we could assign the strand of 
origin of transcripts. In all libraries, the majority of in-
tronic transcripts were from the complementary strand 
to  ENG.  In these healthy low passage number endothe-
lial cells, there were no alignments to the final intron re-
tained in S-endoglin.
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 Fig. 4. Natural and recombinant endoglin variants.  A Illustration 
of the variants with respect to the transmembrane domain and cy-
toplasmic tail (end. = endoglin). L-endoglin and S-endoglin are 
naturally occurring endoglin species; the artificial mutants have 
the 2 cytoplasmic serine residues conserved between L- and S-en-
doglin mutated to alanines (Pmut), or a stop codon in place of the 
second cytoplasmic amino acid of endoglin (I588X; Stop).  B West-
ern blot data of total cell protein extracted from L6E9 cells stably 
transfected with L-endoglin (lane 1), or the mock-transfected L6E9 
cells transiently transfected with expression vectors for S-endoglin 
(lane 3), the truncated L-endoglin I588X stop mutant (lane 4) or 
the phosphorylation mutant (lane 5).  C Modulation of PAI-1 pro-
moter activity by stable expression of L-endoglin in L6E9 rat myo-
blasts (lanes 2–5) and subsequent modulation by transient trans-
fection of empty vector (lanes 1 and 2) or other endoglin species 
(lanes 3–5): Basal PAI-1 activity was significantly (p < 0.0001) 
downregulated by stable transfection of L-endoglin. Transient 
transfection of S-endoglin, the truncation mutant, but not the 
phosphorylation mutant resulted in PAI-1 activities not different 
to the mock stable transfectants, L6E9 rat myoblasts not expressing 
L-endoglin.  D Modulation of c-myc and α-actin expression in 
mock-transfected L6E9 or L6E9 stably expressing L-endoglin fol-
lowing transient transfection with an empty vector (mock; L-en-
doglin); S-endoglin or the truncated endoglin construct, before 
24 h treatment with normal media or media supplemented with 
3 μg/ml TGF-β1. 
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A B C
 Fig. 5. Transcribed fragments across regions of the  ENG  locus de-
leted in HHT mutations. Colour-coded R-plot data for 7 endothe-
lial cell libraries, with exons represented by blue boxes, repeat re-
gions by black boxes, and individual library alignments by the co-
loured lines (key, samples 2–8). Note  ENG  is on the minus strand, 
so 5 ′ to 3 ′ is represented right to left.  A Replicate alignments to 
exons 2, 3 and 14.  B Alignments to regions spanning exon 9A–11, 
demonstrating replicate alignments to exons and to non-repetitive 
intronic regions.  C Illustration of non-unique alignments to re-
petitive regions (including the  Alu elements responsible for a 2-kb 
 ENG  deletion spanning exon 8 [Shovlin et al., 1997]). Note that the 
transcripts responsible for these very high alignments to repetitive 
regions will have originated throughout the genome and are not 
necessarily from the  ENG  locus. 
STOP
Pre-mRNA
EJC EJC EJC EJC EJC
Cap AAAAAn
Processing
Translation CHX
Protein
STOP
EJC EJC EJC EJC EJC
Cap AAAAAn
STOP
Pioneer round translationCHX
STOP
EJC
Cap AAAAAn
PTC
Degradation by NMD
> 50–55 nt
STOP
Cap AAAAAn
Pioneer round translationCHX
 Fig. 6. Nonsense-mediated decay (NMD). A single gene locus is 
transcribed into a pre-mRNA containing all exons and introns. 
The left panel illustrates normal splicing when proteins of the exon 
junction complex (EJC) are deposited  ∼ 20–24 nucleotides up-
stream of exon-exon boundaries. EJCs are displaced by the scan-
ning ribosome in the ‘pioneer’ round of translation. The right pan-
el illustrates an RNA with a premature termination codon (PTC), 
that is a stop codon more than 50–55 nucleotides upstream of the 
final exon-exon boundary. During the pioneer round of transla-
tion, EJCs downstream of PTCs are not displaced, triggering deg-
radation by NMD, an mRNA surveillance system. Cap = 7-Meth-
ylguanosine; CHX = cycloheximide, a naturally occurring antibi-
otic that inhibits translation and therefore inhibits NMD; STOP = 
termination codon. 
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 Discussion 
 Modern molecular data and insights need to be incor-
porated into our understanding of mutational mecha-
nisms of disease. The data presented in this article high-
light the relevance of NMD for PTC-generating muta-
tions, and potential implications of intronic transcribed 
fragments from loci deleted or duplicated by large ge-
nomic deletions, insertions or rearrangements.
 For PTC-generating endoglin mutations, current mo-
lecular perspectives suggest that the majority will fail to 
generate an RNA product from which translation of trun-
cated proteins could occur. For  ENG  and  SMAD4 , the 
most commonly reported mutations generate stop co-
dons either directly or indirectly by out-of-frame inser-
tions or deletions. These are often assumed to have the 
potential to generate truncated proteins. Where endoge-
nous mutated endoglin protein species are examined by 
metabolic labelling of cells, however, it is rare for any mu-
tant species to be detected [Pece et al., 1997; Pece-Barba-
ra et al., 1999; Cymerman et al., 2000]. The data present-
ed here highlight that such mutations are most likely to 
result in NMD of the mutated mRNA, as discussed fur-
ther below.
 One of the puzzles in HHT circles has been the absence 
of detected mutations in the final coding exon. At first 
sight, this may suggest that S-endoglin, which utilises 
only 7 amino acids of the L-endoglin cytoplasmic tail 
( fig. 2 ), could be the moiety responsible for HHT patho-
genesis. However, the presented data provide alternate 
explanations for the lack of HHT genomic mutations at 
these sites. The absence of frameshift mutations leading 
to exon 13 and 14 stop codons is explained by the absence 
of any alternate reading frame stop codons. For missense 
substitutions, the absence of an effect of substituting the 
conserved serine residues ( fig. 4 ) implies that there is no 
single cytoplasmic amino acid residue where modifica-
tions have been shown to generate a null allele. The ab-
sence of nonsense mutations requiring a specific nucleo-
tide change may not be surprising given that only 97
single nucleotide substitutions were reported as HHT 
mutations for the entire  ENG  coding sequence (www.
hhtmutation.org at time of analysis, now at www.arup.
utah.edu/database/hht/), but a further explanation is de-
tailed below. Overall, the data begin to explain the miss-
ing mutations, and neither support or refute the possibil-
ity that mutated S-endoglin causes HHT.
 The detection of transcribed transcripts within intron-
ic regions of the  ENG locus deleted in HHT disease-caus-
ing mutations should not be surprising. Cellular RNA is 
normally quoted as comprising mRNAs ( ∼ 2–4%), rRNAs 
( ∼ 80%), tRNAs ( ∼ 15%) and small RNAs ( ∼ 1%) [Lind-
berg and Lundeberg, 2010]. However, the development of 
high-throughput technologies such as tiling arrays and 
next-generation sequencing have made it evident that a 
large proportion of the eukaryotic intronic and intergen-
ic regions of the genome are transcribed, in what is known 
as ‘pervasive transcription’. The biological consequences 
are still being elucidated and although most of these RNA 
fragments are not protein coding, some are very stable, 
highly conserved or regulated under different conditions, 
suggesting that they are functional with potential regula-
tory roles [Kapranov et al., 2002; Berretta and Morillon, 
2009]. The detection of such transcripts within intronic 
regions of the  ENG  locus deleted in HHT disease-causing 
mutations highlights additional transcript changes that 
will be incurred by these multiexon deletion, insertion or 
rearrangement  ENG  mutations in HHT.
 Overall, the data suggest that any phenotypic differ-
ences ascribable to different  ENG  mutation types are un-
likely to segregate by the conventional mutational sub-
groupings illustrated in  figure 1 . The key distinction is the 
generation or non-generation of PTCs, with multiexon 
deletions, insertions or rearrangements predicted to have 
a more complex phenotype because affected patients will 
have a different copy number of other intronic tran-
scribed fragments. Such predictions can and should be 
tested experimentally by the laboratories that have de-
rived endothelial cells from HHT patients harbouring 
different  ENG mutations. For example, loss of an exon 
due to a splice-site mutation and exon skip may differ 
functionally to loss of the same exon due to a large dele-
tion spanning the exon and neighbouring intronic re-
gions.
 To understand why mRNAs containing stop codon 
mutations will usually be degraded, it is helpful to con-
sider NMD in a more general context. NMD is one of a 
group of highly conserved quality control surveillance 
mechanisms operating in normal cells to recognise and 
degrade defective mRNAs, which if translated could pro-
duce harmful aberrant proteins. Such RNAs can be gen-
erated independently of any genomic DNA mutations, as 
a result of errors during transcription, RNA processing or 
RNA packaging. NMD is known to be translation-depen-
dent in eukaryotes, as it can be reversed by protein syn-
thesis inhibitors such as anisomycin and cycloheximide 
[Carter et al., 1996]. NMD also depends upon normal 
RNA splicing mechanisms: PTC-containing mRNAs de-
rived from intronless genes (where no splicing occurs) do 
not undergo NMD [Brocke et al., 2002]. As illustrated in 
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 figure 6 , during RNA splicing, exon-exon junctions are 
marked by exon junction complexes (EJCs) which are de-
posited  ∼ 20–24 nucleotides upstream of each exon-exon 
junction. The current NMD model in mammals suggests 
that during the initial (pioneer) round of translation, the 
scanning ribosome displaces all the EJCs on an mRNA 
which would normally be upstream of the stop codon. 
Upon recognition of the stop codon, a termination com-
plex is formed. In PTC-containing mRNAs, however, 
EJCs downstream of the PTC are not displaced by scan-
ning the ribosome. This allows the termination complex 
to interact with the EJC, triggering NMD [Maquat, 2005]. 
Despite the frequency with which they are generated, 
PTC-containing mRNAs are low in abundance in vivo, 
unless unmasked by treating cells with protein synthesis 
inhibitors such as CHX [Carter et al., 1996], or RNA in-
terference depletion of essential NMD factors [McGlincy 
and Smith, 2008].
 Historically, PTC-containing mRNAs were thought to 
be translated into truncated proteins based on experi-
mental evidence of gain of function or dominant negative 
activities. Such studies used in vitro-generated cDNA 
constructs [Gong et al., 2007]. As for intronless genes 
[Brocke et al. 2002], cDNA constructs do not undergo 
splicing, do not contain EJCs, and therefore do not trigger 
NMD in mammalian cell lines [Gong et al., 2007]. Thus, 
many diseases thought to be due to gain of function or 
dominant negative effects may be more likely to be due to 
loss of function or haploinsufficiency. However, NMD is 
not generally appreciated as a concept relevant to DNA 
mutations. In September 2011, Web of Science search 
terms ‘nonsense, decay, mutation’ identified only 972 
publications (including 50–90 per year since 2006), com-
pared to 32,112 referring to ‘truncated, protein, muta-
tion’.
 The absence of  ENG exon 13 and 14 mutations in HHT 
point to other generic processes. The widespread preva-
lence of insertions and deletions (indels, estimated to af-
fect 30% of the human genome [Zhang et al., 2009]) high-
lights the importance of genomic sequence toleration of 
out-of-frame indels. Genome-wide analyses by others 
have addressed mechanisms relating to codon nucleotide 
use [Cusack et al., 2011; Wilke et al., 2011], but for  ENG , 
we examined from a different perspective. For indels gen-
erating stop codons more than 55 nucleotides upstream 
of the final exon-exon boundary, the resultant PTCs will 
trigger NMD. For coding sequences beyond this safety 
net, it would be predicted that alternate strategies need to 
be employed. The absence of stop codons in any of the 3 
reading frames throughout the last 55 nucleotides of exon 
13, and the 124 coding nucleotides of exon 14 suggest that 
for L-endoglin, the most prevalent endoglin species, se-
lective pressures may have limited the opportunity for in-
dels to generate a natural stop codon which would gener-
ate functional truncated species ( fig. 4 ) [Lux et al., 2000]. 
There is no particular reason why the phenotypic result 
would resemble that of a null allele and cause HHT. Yet 
for endoglin, there is 1 HHT-generating frameshift muta-
tion predicted to generate a natural stop codon in exon 14 
( fig. 3 ).  ENG  mutation c.1733_1737delACCTG changes 
170 amino acids before a novel natural stop codon in exon 
14. Similarly, were S-endoglin to be implicated in HHT 
pathogenesis, there are 8 natural stop codons generated 
in exon 12 by frameshift HHT mutations in exons 11 and 
12 ( fig. 3 ). None of these should undergo NMD. How-
ever, all 9 disrupt the transmembrane domain encoded by 
exon 12: functional nulls at a protein level might therefore 
explain the phenotypic similarity with other  ENG  null al-
leles.
 In conclusion, using modern molecular perspectives 
to re-examine HHT mutations suggests that any pheno-
typic differences are unlikely to segregate by the conven-
tional mutational subgroupings. Not only may additional 
data be required before a pathogenic role can be ascribed 
to potential missense  ENG  mutations [McDonald et al., 
2009], but similar cautions may also need to be applied to 
small inframe indels to prevent provision of incorrect ge-
notypic predictions. From the data presented in this ar-
ticle, we predict that instead of nonsense or missense mu-
tations being more severe (as predicted by earlier mod-
els), it should be the multiexon deletions that have a more 
complex phenotype. The data also lead to the prediction 
that while nonsense mutations may be identified in the 
final exons of endoglin, when these occur, the phenotype 
will not be that of HHT.
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